COVID-19 is an emerging infectious disease by formal definition, though it is now transitioning into what scientists call an endemic phase. The World Health Organization defines an emerging infectious disease as one that has appeared in a population for the first time or is rapidly spreading to new areas or new groups of people. SARS-CoV-2, the virus behind COVID-19, first appeared in humans in late 2019 and spread globally within months, fitting that definition squarely. But the story doesn’t end there, because the classification of a disease shifts as populations build immunity and the virus settles into predictable patterns.
What Makes a Disease “Emerging”
The WHO uses a straightforward two-part definition. A disease qualifies as emerging if it either affects a human population for the first time or if an existing disease is rapidly increasing in case numbers or geographic reach. By this standard, COVID-19 was a textbook emerging infectious disease when it appeared. No human immune system had encountered SARS-CoV-2 before, there was no vaccine, and the virus swept across every continent within weeks.
Other familiar examples of emerging diseases include Ebola, SARS (the 2003 outbreak), MERS, and Zika. What they share is novelty: the pathogen is either brand-new to humans or has jumped into populations that have no prior immunity. COVID-19 joined that list in early 2020 and triggered a public health emergency of international concern, the WHO’s highest level of global alert.
How SARS-CoV-2 Emerged
SARS-CoV-2 is suspected to have originated in bats. The virus uses a receptor called ACE2 to enter human cells, and that receptor is highly conserved across mammal species, which helps explain why the virus can infect such a wide range of animals. The leading hypotheses for how it reached humans include direct spillover from bats after a random mutation, gradual adaptation through a less-virulent ancestor picking up new mutations, or transmission through an intermediate animal host that bridged the gap between bats and people.
The broader forces behind this kind of spillover are well understood. Deforestation, habitat fragmentation, intensified livestock production, and wildlife trade all increase the frequency of contact between humans and wild animals. These environmental disturbances create more opportunities for animal viruses to jump species. COVID-19 fits a pattern that infectious disease experts have warned about for decades: as human activity pushes deeper into wildlife habitats, the chances of a novel pathogen crossing into human populations go up.
From Emergency to Established Threat
On May 5, 2023, the WHO Director-General declared that COVID-19 no longer constituted a public health emergency of international concern. The official language was telling: COVID-19 was described as “an established and ongoing health issue.” That phrasing reflects a disease that hasn’t disappeared but has shifted from its explosive, unpredictable early phase into something more familiar and manageable for health systems.
The numbers illustrate how dramatically the situation has changed. At its deadliest peak in late January 2021, COVID-19 killed over 103,000 people worldwide in a single week. By early 2026, reported deaths had dropped to roughly 1,800 over a 28-day period globally, a fraction of the early toll. This decline reflects widespread immunity from both vaccination and prior infection, not the disappearance of the virus itself.
The Shift Toward Endemicity
Scientists distinguish between an emerging disease and an endemic one. An endemic disease circulates continuously in a population at relatively predictable levels. Research published in Science outlined the key factors governing this transition for COVID-19. As population-wide immunity builds through infection and vaccination, primary infections increasingly shift toward younger age groups, particularly children encountering the virus for the first time. This is the same pattern seen with the four coronaviruses that cause common colds, all of which likely caused major outbreaks when they first entered human populations before settling into mild, recurring childhood infections.
The modeling suggests that once COVID-19 fully reaches its endemic phase and most first exposures happen in childhood, the disease could become no more severe than a common cold for the majority of people. That transition isn’t instantaneous. It depends on how quickly the virus spreads, how long immunity lasts, and whether new variants emerge with significantly different properties.
Why New Variants Keep It on the Radar
All viruses mutate, and most mutations have little practical effect. But some changes in SARS-CoV-2 alter how easily it spreads, how severe the resulting illness is, or how well vaccines and treatments work against it. Starting in late 2020, the WHO began formally tracking variants of interest and variants of concern to coordinate the global response.
This ongoing evolution is one reason COVID-19 still carries some characteristics of an emerging threat even as it transitions toward endemicity. The virus continues to circulate at high levels worldwide, and mutations can arise not only in human populations but also in animal reservoirs and in people with chronic infections whose immune systems can’t fully clear the virus. The U.S. National Institute of Allergy and Infectious Diseases still lists SARS-CoV-2 alongside SARS and MERS on its biodefense and emerging infectious disease pathogen priority list, reflecting the view that the virus remains a research and surveillance priority.
Preventing the Next Emergence
COVID-19 has become a central case study in the One Health framework, which treats human health, animal health, and environmental health as deeply interconnected. The principle is straightforward: because viruses like SARS-CoV-2 thrive at the human-animal interface and are driven by environmental conditions, preventing future pandemics requires monitoring all three domains simultaneously. The goal is to catch infectious diseases before they become epidemics rather than reacting after they’ve spread.
For COVID-19 specifically, this means continued surveillance of the virus in both human and animal populations. SARS-CoV-2 has already been detected in deer, mink, cats, and other mammals, and each animal reservoir represents a potential source of new variants that could spill back into humans. With global population growth and urbanization increasing the pressure on wildlife habitats, the conditions that allowed COVID-19 to emerge in the first place are, if anything, intensifying.
So the most accurate answer is that COVID-19 emerged as a novel infectious disease in 2019, still retains some emerging characteristics due to ongoing viral evolution, and is gradually settling into an endemic pattern. It occupies a gray zone: no longer the explosive unknown it was five years ago, but not yet the fully predictable seasonal presence that older coronaviruses have become.